Clinical Trial Update: Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma [Phase 1]

View source ↗

Summary

Phase 1 trial of pembrolizumab in pediatric patients with recurrent or refractory high-grade gliomas, including diffuse intrinsic pontine glioma, ependymoma, me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Constitutional Mismatch Repair Deficiency Syndrome
• Diffuse Intrinsic Pontine Glioma
• Ependymoma
• Lynch Syndrome
• Malignant Glioma
• Medulloblastoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome | Phase 1 | Status: ACTIVE_NOT_RECRUITING